Nasus Pharma Stock Market Value
| NSRX Stock | 5.90 0.90 18.00% |
| Symbol | Nasus |
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Nasus Pharma. Anticipated expansion of Nasus directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Nasus Pharma assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Understanding Nasus Pharma requires distinguishing between market price and book value, where the latter reflects Nasus's accounting equity. The concept of intrinsic value - what Nasus Pharma's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Nasus Pharma's price substantially above or below its fundamental value.
It's important to distinguish between Nasus Pharma's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Nasus Pharma should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Nasus Pharma's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Nasus Pharma 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Nasus Pharma's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Nasus Pharma.
| 11/26/2025 |
| 02/24/2026 |
If you would invest 0.00 in Nasus Pharma on November 26, 2025 and sell it all today you would earn a total of 0.00 from holding Nasus Pharma or generate 0.0% return on investment in Nasus Pharma over 90 days. Nasus Pharma is related to or competes with Lite Strategy, Nutriband, Adicet Bio, Tscan Therapeutics, XBiotech, Fortress Biotech, and Gain Therapeutics. Nasus Pharma is entity of United States. It is traded as Stock on NYSE MKT exchange. More
Nasus Pharma Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Nasus Pharma's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Nasus Pharma upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.03) | |||
| Maximum Drawdown | 36.48 | |||
| Value At Risk | (9.60) | |||
| Potential Upside | 12.18 |
Nasus Pharma Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Nasus Pharma's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Nasus Pharma's standard deviation. In reality, there are many statistical measures that can use Nasus Pharma historical prices to predict the future Nasus Pharma's volatility.| Risk Adjusted Performance | (0.01) | |||
| Jensen Alpha | (0.12) | |||
| Total Risk Alpha | (0.68) | |||
| Treynor Ratio | 0.2722 |
Nasus Pharma February 24, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.01) | |||
| Market Risk Adjusted Performance | 0.2822 | |||
| Mean Deviation | 4.31 | |||
| Coefficient Of Variation | (4,351) | |||
| Standard Deviation | 6.4 | |||
| Variance | 40.96 | |||
| Information Ratio | (0.03) | |||
| Jensen Alpha | (0.12) | |||
| Total Risk Alpha | (0.68) | |||
| Treynor Ratio | 0.2722 | |||
| Maximum Drawdown | 36.48 | |||
| Value At Risk | (9.60) | |||
| Potential Upside | 12.18 | |||
| Skewness | 0.7303 | |||
| Kurtosis | 2.17 |
Nasus Pharma Backtested Returns
Nasus Pharma has Sharpe Ratio of -0.0112, which conveys that the firm had a -0.0112 % return per unit of risk over the last 3 months. Nasus Pharma exposes twenty-four different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please verify Nasus Pharma's Mean Deviation of 4.31, risk adjusted performance of (0.01), and Standard Deviation of 6.4 to check out the risk estimate we provide. The company secures a Beta (Market Risk) of -0.58, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Nasus Pharma are expected to decrease at a much lower rate. During the bear market, Nasus Pharma is likely to outperform the market. At this point, Nasus Pharma has a negative expected return of -0.075%. Please make sure to verify Nasus Pharma's maximum drawdown, daily balance of power, as well as the relationship between the Daily Balance Of Power and period momentum indicator , to decide if Nasus Pharma performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.27 |
Weak reverse predictability
Nasus Pharma has weak reverse predictability. Overlapping area represents the amount of predictability between Nasus Pharma time series from 26th of November 2025 to 10th of January 2026 and 10th of January 2026 to 24th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Nasus Pharma price movement. The serial correlation of -0.27 indicates that nearly 27.0% of current Nasus Pharma price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.27 | |
| Spearman Rank Test | -0.46 | |
| Residual Average | 0.0 | |
| Price Variance | 0.39 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Nasus Stock Analysis
When running Nasus Pharma's price analysis, check to measure Nasus Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nasus Pharma is operating at the current time. Most of Nasus Pharma's value examination focuses on studying past and present price action to predict the probability of Nasus Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nasus Pharma's price. Additionally, you may evaluate how the addition of Nasus Pharma to your portfolios can decrease your overall portfolio volatility.